Compass Pathways reports six‑month data confirming durable profile of COMP360

3 hours ago

Add Comment

by David Miller

947 Views

Second phase 3 trial shows sustained benefit and supports forthcoming regulatory submission

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

You may also like

About the author

David Miller

Leave a Comment X